Drivers of Start-Up Delays in Global Randomized Clinical Trials

Overview

Journal Ther Innov Regul Sci

Specialties General Medicine
Pharmacology

Date 2020 Sep 22

PMID 32959207

Citations 17

Authors

Jennifer Lai

Leila Forney

Daniel L Brinton

Kit N Simpson

Affiliations

Soon will be listed here.

Abstract

Background: Global, randomized clinical trials are extremely complex. Trial start-up is a critical phase and has many opportunities for delay which adversely impact the study timelines and budget. Understanding factors that contribute to delay may help clinical trial managers and other stakeholders to work more efficiently, hastening patient access to potential new therapies.

Methods: We reviewed the available literature related to start-up of global, Phase III clinical trials and then created a fishbone diagram detailing drivers contributing to start-up delays. The issues identified were used to craft a checklist to assist clinical trial managers in more efficient trial start-up.

Results: We identified key drivers for start-up delays in the following categories: regulatory, contracts and budgets, insurance, clinical supplies, site identification and selection, site activation, and inefficient processes/pitfalls.

Conclusion: Initiating global randomized clinical trials is a complex endeavor, and reasons for delay are well documented in the literature. By using a checklist, clinical trial managers may mitigate some delays and get clinical studies initiated as soon as possible.

Citing Articles

Effects of the Paediatric Regulation funding on the development of off-patent medicines in children.

Ruggieri L, Torretta S, Giannuzzi V, Natale A, Felisi M, Ceci A Front Med (Lausanne). 2025; 11:1473862.

PMID: 39949386 PMC: 11823639. DOI: 10.3389/fmed.2024.1473862.

Defining methods to improve eSource site start-up practices.

Cramer A, King L, Buckley M, Casteleyn P, Ennis C, Hamidi M Contemp Clin Trials Commun. 2024; 42():101391.

PMID: 39651464 PMC: 11625275. DOI: 10.1016/j.conctc.2024.101391.

Flourishing and job satisfaction in employees working in UK clinical trial units: a national cross-sectional survey.

Hall S, Riga E, Sprange K, Hagan P, Carr L, Taylor J BMC Health Serv Res. 2024; 24(1):1522.

PMID: 39623423 PMC: 11610179. DOI: 10.1186/s12913-024-11986-x.

Commentary: The North West London Clinical Trials Alliance: efficiency and innovation in clinical trial delivery.

Kierkegaard P, Su B, Wong R, Boffito M, Balendra S Trials. 2024; 25(1):509.

PMID: 39069627 PMC: 11285441. DOI: 10.1186/s13063-024-08344-x.

What Is Ailing Oncology Clinical Trials? Can We Fix Them?.

Mittal A, Moore S, Navani V, Jiang D, Stewart D, Liu G Curr Oncol. 2024; 31(7):3738-3751.

PMID: 39057147 PMC: 11276279. DOI: 10.3390/curroncol31070275.

References

Abbott D, Califf R, Morrison B, Pierre C, Bolte J, Chakraborty S . Cycle Time Metrics for Multisite Clinical Trials in the United States. Ther Innov Regul Sci. 2018; 47(2):152-160. DOI: 10.1177/2168479012464371. View

Briel M, Speich B, von Elm E, Gloy V . Comparison of randomized controlled trials discontinued or revised for poor recruitment and completed trials with the same research question: a matched qualitative study. Trials. 2020; 20(1):800. PMC: 6937940. DOI: 10.1186/s13063-019-3957-4. View

Tang M, Joensuu H, Simes R, Price T, Yip S, Hague W . Challenges of international oncology trial collaboration-a call to action. Br J Cancer. 2019; 121(7):515-521. PMC: 6889481. DOI: 10.1038/s41416-019-0532-4. View

Choi Y, Jeon H, Kim S, In Y, Park S, Park M . A Trial Activation Initiative to Accelerate Trial Opening in an Academic Medical Center. Ther Innov Regul Sci. 2018; 49(2):234-238. DOI: 10.1177/2168479014554399. View

Kenyon G, Mendelow A, Gregson B, Rowan E . Obtaining regulatory approval for multicentre randomised controlled trials: experiences in the STICH II trial. Br J Neurosurg. 2011; 25(3):352-6. DOI: 10.3109/02688697.2010.551675. View

Atassi N, Yerramilli-Rao P, Szymonifka J, Yu H, Kearney M, Grasso D . Analysis of start-up, retention, and adherence in ALS clinical trials. Neurology. 2013; 81(15):1350-5. PMC: 3806927. DOI: 10.1212/WNL.0b013e3182a823e0. View

Corneli A, Pierre C, Hinkley T, Lin L, Fordyce C, Hamre G . One and done: Reasons principal investigators conduct only one FDA-regulated drug trial. Contemp Clin Trials Commun. 2018; 6:31-38. PMC: 5936741. DOI: 10.1016/j.conctc.2017.02.009. View

Kantarjian H, Stewart D, Zwelling L . Cancer research in the United States: dying by a thousand paper cuts. Cancer. 2013; 119(21):3742-5. DOI: 10.1002/cncr.28193. View

Kiriakis J, Gaich N, Johnston S, Kitterman D, Rosenblum D, Salberg L . Observational study of contracts processing at 29 CTSA sites. Clin Transl Sci. 2013; 6(4):279-85. PMC: 3740442. DOI: 10.1111/cts.12073. View

10.

Dilts D, Sandler A . Invisible barriers to clinical trials: the impact of structural, infrastructural, and procedural barriers to opening oncology clinical trials. J Clin Oncol. 2006; 24(28):4545-52. DOI: 10.1200/JCO.2005.05.0104. View

11.

Lamberti M, Wilkinson M, Harper B, Morgan C, Getz K . Assessing Study Start-up Practices, Performance, and Perceptions Among Sponsors and Contract Research Organizations. Ther Innov Regul Sci. 2018; 52(5):572-578. DOI: 10.1177/2168479017751403. View

12.

Xu L, Gao H, Kaitin K, Shao L . Reforming China's drug regulatory system. Nat Rev Drug Discov. 2018; 17(12):858-859. DOI: 10.1038/nrd.2018.150. View

13.

Hurtado-Chong A, Joeris A, Hess D, Blauth M . Improving site selection in clinical studies: a standardised, objective, multistep method and first experience results. BMJ Open. 2017; 7(7):e014796. PMC: 5734283. DOI: 10.1136/bmjopen-2016-014796. View

14.

Cheng S, Dietrich M, Dilts D . A sense of urgency: Evaluating the link between clinical trial development time and the accrual performance of cancer therapy evaluation program (NCI-CTEP) sponsored studies. Clin Cancer Res. 2010; 16(22):5557-63. PMC: 3050630. DOI: 10.1158/1078-0432.CCR-10-0133. View

15.

Umscheid C, Margolis D, Grossman C . Key concepts of clinical trials: a narrative review. Postgrad Med. 2011; 123(5):194-204. PMC: 3272827. DOI: 10.3810/pgm.2011.09.2475. View

16.

Treweek S, Bevan S, Bower P, Campbell M, Christie J, Clarke M . Trial Forge Guidance 1: what is a Study Within A Trial (SWAT)?. Trials. 2018; 19(1):139. PMC: 5824570. DOI: 10.1186/s13063-018-2535-5. View

17.

Sullivan G . Getting off the "gold standard": randomized controlled trials and education research. J Grad Med Educ. 2012; 3(3):285-9. PMC: 3179209. DOI: 10.4300/JGME-D-11-00147.1. View

18.

Minisman G, Bhanushali M, Conwit R, Wolfe G, Aban I, Kaminski H . Implementing clinical trials on an international platform: challenges and perspectives. J Neurol Sci. 2011; 313(1-2):1-6. PMC: 3254780. DOI: 10.1016/j.jns.2011.10.004. View

19.

Rodon J, Soria J, Berger R, Batist G, Tsimberidou A, Bresson C . Challenges in initiating and conducting personalized cancer therapy trials: perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium trial. Ann Oncol. 2015; 26(8):1791-8. PMC: 5006164. DOI: 10.1093/annonc/mdv191. View

20.

Crow R, Hart K, McDermott M, Tawil R, Martens W, Herr B . A checklist for clinical trials in rare disease: obstacles and anticipatory actions-lessons learned from the FOR-DMD trial. Trials. 2018; 19(1):291. PMC: 5968578. DOI: 10.1186/s13063-018-2645-0. View